JP2010502762A - ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物 - Google Patents

ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物 Download PDF

Info

Publication number
JP2010502762A
JP2010502762A JP2009527796A JP2009527796A JP2010502762A JP 2010502762 A JP2010502762 A JP 2010502762A JP 2009527796 A JP2009527796 A JP 2009527796A JP 2009527796 A JP2009527796 A JP 2009527796A JP 2010502762 A JP2010502762 A JP 2010502762A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
modified release
factor
release pharmaceutical
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009527796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502762A5 (OSRAM
Inventor
オマル・アブデルファッター・アブ−バケル
フ・ヨン
キンバリー・アン・レイミー
ロバート・フランシス・レポスキー
レナン・パン
カムレシュ・ラメシュチャンドラ・ペイテル
ラフル・パラシャル・シュクラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010502762(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2010502762A publication Critical patent/JP2010502762A/ja
Publication of JP2010502762A5 publication Critical patent/JP2010502762A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009527796A 2006-09-12 2007-09-10 ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物 Withdrawn JP2010502762A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12
PCT/EP2007/059443 WO2008031782A1 (en) 2006-09-12 2007-09-10 Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor

Publications (2)

Publication Number Publication Date
JP2010502762A true JP2010502762A (ja) 2010-01-28
JP2010502762A5 JP2010502762A5 (OSRAM) 2010-10-28

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527796A Withdrawn JP2010502762A (ja) 2006-09-12 2007-09-10 ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物

Country Status (16)

Country Link
US (1) US20090285887A1 (OSRAM)
EP (1) EP2061439A1 (OSRAM)
JP (1) JP2010502762A (OSRAM)
KR (1) KR20090052346A (OSRAM)
CN (1) CN101516355A (OSRAM)
AR (1) AR062721A1 (OSRAM)
AU (1) AU2007296311A1 (OSRAM)
BR (1) BRPI0716234A2 (OSRAM)
CA (1) CA2662542A1 (OSRAM)
CL (1) CL2007002618A1 (OSRAM)
EA (1) EA200970267A1 (OSRAM)
IL (1) IL197295A0 (OSRAM)
MX (1) MX2009002669A (OSRAM)
PE (1) PE20080661A1 (OSRAM)
TW (1) TW200824723A (OSRAM)
WO (1) WO2008031782A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521226A (ja) * 2010-02-25 2013-06-10 ブリストル−マイヤーズ スクイブ カンパニー アピキサバン製剤
JP2015517998A (ja) * 2012-04-13 2015-06-25 ハンミ ファーム． シーオー．， エルティーディー． 硬カプセル中にカプセル化された複数単位球状錠剤（ｍｕｓｔ）を含む複合製剤およびこれらの製造方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773816E (pt) 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
RS55940B1 (sr) 2005-12-28 2017-09-29 Vertex Pharma Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US20120189693A1 (en) * 2009-06-25 2012-07-26 Elite Laboratories, Inc. Oral dosage forms
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
MX2013002353A (es) * 2010-08-27 2013-09-26 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
MX339047B (es) 2010-10-15 2016-05-09 Brain Sentinel Inc Metodo y aparato para detectar convulsiones.
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
EP2854759B1 (en) * 2012-05-24 2019-12-18 ratiopharm GmbH Dosage forms comprising apixaban and matrix former
CN104582692A (zh) 2012-08-28 2015-04-29 中化帝斯曼制药有限公司荷兰公司 包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
US20190046449A1 (en) * 2016-02-25 2019-02-14 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ES2301477T3 (es) * 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521226A (ja) * 2010-02-25 2013-06-10 ブリストル−マイヤーズ スクイブ カンパニー アピキサバン製剤
US9326945B2 (en) 2010-02-25 2016-05-03 Bristol-Myers Squibb Company Apixaban formulations
JP2017226679A (ja) * 2010-02-25 2017-12-28 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ アピキサバン製剤
JP2015517998A (ja) * 2012-04-13 2015-06-25 ハンミ ファーム． シーオー．， エルティーディー． 硬カプセル中にカプセル化された複数単位球状錠剤（ｍｕｓｔ）を含む複合製剤およびこれらの製造方法

Also Published As

Publication number Publication date
CA2662542A1 (en) 2008-03-20
EA200970267A1 (ru) 2009-08-28
KR20090052346A (ko) 2009-05-25
AU2007296311A1 (en) 2008-03-20
AR062721A1 (es) 2008-11-26
US20090285887A1 (en) 2009-11-19
BRPI0716234A2 (pt) 2013-10-15
CL2007002618A1 (es) 2008-03-14
MX2009002669A (es) 2009-03-24
WO2008031782A1 (en) 2008-03-20
PE20080661A1 (es) 2008-06-12
CN101516355A (zh) 2009-08-26
EP2061439A1 (en) 2009-05-27
TW200824723A (en) 2008-06-16
IL197295A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
JP2010502762A (ja) ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物
JP5985719B2 (ja) 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法
EP1441713B1 (en) Modified release tamsulosin tablets
CN101460154B (zh) 包含抗血小板剂和抑酸剂的口服剂型
AU2005213472A1 (en) Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
JP5570426B2 (ja) 固形医薬組成物
JP5749247B2 (ja) 経口用徐放性固形製剤
WO2008066102A1 (en) Sustained release preparation
CN102209546A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
JP2012525323A (ja) 固形製剤
JP2023517844A (ja) ベンズイミダゾール誘導体化合物を含有する医薬組成物
CN103340860A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
CA3210689A1 (en) Fixed-dose pharmaceutical compositions
JP6122879B2 (ja) 固形製剤
JPH11510514A (ja) 経口被覆活性薬物
US20210361582A1 (en) Colchicine salicylate derivatives and methods of treatment
HK1131566B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100910

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110420